Our vision is our passion:

AFFiRiS is dedicated to developing novel immunotherapies for chronic human diseases.

ABOUT US

AFFiRiS is a clinical-stage biopharmaceutical company that pursues the ultimate aim to improve the lives of patients suffering from chronic diseases by providing specific active immunotherapies (SAIT) based on its proprietary patented AFFITOME® technology or designing monocloncal antibodies.

We strive to deliver much‑needed therapies to patients with debilitating and life‑threatening neurodegenerative diseases, such as Huntington’s disease or chronic diseases like hypercholesterolemia.

We aim to surpass currently available treatments.

We focus on unmet medical needs in chronic diseases

Chronic diseases can have devastating effects on the quality of life of patients and family members, and often worsen over time. Currently available treatments for many of these diseases aim to manage symptoms, and do not stop or reverse progression. As a result, chronic diseases often lead to a progressively reduced quality of life. Therefore, better treatments for chronic diseases are needed to give patients healthier, happier, and longer lives.
We embrace this opportunity.

PARKINSON’S
DISEASE

HUNTINGTON’S
DISEASE

MULTIPLE SYSTEM
ATROPHY

Specific Active ImmunoTherapy (SAIT)

Adherence to current therapies can be poor due to complex dosing regimens, and the treatment of many chronic diseases is still inadequate. Using our unique AFFITOME technology, we are developing Specific Active ImmunoTherapy (SAIT), which stimulates the body to find and fight proteins central to the development and progression of chronic diseases. SAIT induces a long‑lasting target-specific immune response, which may be generated by far less frequent dosing regimens (e.g., once or twice a year)
SAIT is an exciting prospect.

Our pipeline

We focus on identifying proteins that are involved in the development and progression of chronic human diseases, and establishing novel SAIT treatments against potentially pathogenic forms of these proteins using our unique AFFITOME technology. SAIT has successfully demonstrated proof of concept in both preclinical and clinical studies. Our most advanced product candidates are ready to enter Phase II clinical trials.
We are moving forward.

PIPELINE

CLINICAL TRIALS

PUBLICATIONS

Collaborators

We intensively collaborate with a range of companies, universities, and foundations during the development of our novel immunotherapies.
Be part of our journey.

Investors

We have a portfolio of immunotherapies that can be used in the treatment of a variety of chronic diseases and are open for collaborations.
Partner with us.

Contact us